SIB-IMRT combined with apatinib for unresectable hepatocellular carcinoma in patients with poor response to transarterial chemoembolization
Background: Radiotherapy combined with apatinib exhibits synergistic anti-tumor effect, while the application of simultaneous integrated boost intensity modulated radiotherapy (SIB-IMRT) combined with apatinib in HCC patients is scarce. Hence, this study aimed to explore the treatment response, surv...
Main Authors: | Liu, X. (Author), Luo, J. (Author), Peng, D. (Author), Yang, F. (Author), Zhang, L. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier Masson s.r.l.
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
by: Zhang W, et al.
Published: (2021-07-01) -
Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
by: Xuefeng Kan, et al.
Published: (2020-07-01) -
Advanced Hepatocellular Carcinoma With Hepatic Arterioportal Shunts: Combination Treatment of Transarterial Chemoembolization With Apatinib
by: Tao Sun, et al.
Published: (2020-12-01) -
Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma:A Propensity Score Matching Analysis
by: Qiu Z, et al.
Published: (2019-11-01) -
Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study
by: Yanyan Cao, et al.
Published: (2021-08-01)